Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.38 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | MARS1 | P56192 | 1/20 | 0.31 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL6361607 | 0.95 | BHMT (0.36) | BHMTBHMT2RNPEPMETAP2METAP1 | |
| Methionine SCHEMBL7649643 | 0.91 | BHMT (0.37) | BHMTBHMT2RNPEPNOS2NOS3 | |
| SCHEMBL1579771 | 0.87 | RNPEP (0.41) | BHMTBHMT2RNPEPMETAP2METAP1 | |
| SCHEMBL3995873 | 0.85 | METAP2 (0.32) | METAP2METAP1 | |
| Methionine SCHEMBL7343873 | 0.85 | BHMT (0.34) | BHMTBHMT2RNPEPNOS2NOS3 | |
| SCHEMBL2260606 | 0.85 | RNPEP (0.44) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Glycine SCHEMBL4361131 | 0.82 | BHMT (0.37) | BHMTBHMT2RNPEPMETAP2METAP1 | |
| Glutamine SCHEMBL5957029 | 0.82 | ALOX15 (0.37) | BHMTBHMT2 | |
| SCHEMBL692980 | 0.81 | BHMT (0.31) | BHMTBHMT2 | |
| SCHEMBL5704260 | 0.81 | NOS3 (0.36) | NOS2NOS3NOS1IDO1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4120997-A1 | TREATMENT OF UPPER FACIAL LINES | Ipsen Biopharm Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4118096-A1 | STABILISED VIRAL FUSION PROTEINS | Oxford University Innovation Limited (GB) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021186167-A1 | TREATMENT OF UPPER FACIAL LINES | IPSEN BIOPHARM LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021181121-A1 | STABILISED VIRAL FUSION PROTEINS | OXFORD UNIVERSITY INNOVATION LIMTIED (GB) | 2021-09-16 | — | — | WO | disclosed |
| EP-2703491-B1 | PROTEIN AND NUCLEIC ACID DELIVERY VEHICLES, COMPONENTS AND MECHANISMS THEREOF | UNIV AMERICA CATHOLIC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2703491-A1 | Protein and nucleic acid delivery vehicles, components and mechanisms thereof | The Catholic University Of America (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2542681-A2 | PROTEIN AND NUCLEIC ACID DELIVERY VEHICLES, COMPONENTS AND MECHANISMS THEREOF | The Catholic University Of America (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011125054-A2 | PROTEIN AND NUCLEIC ACID DELIVERY VEHICLES, COMPONENTS AND MECHANISMS THEREOF | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-1141274-A2 | SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING THEM FOR THERAPY | ZymoGenetics, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040716-A2 | SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING THEM FOR THERAPY | ZYMOGENETICS, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-1007646-A1 | PROTEASE VARIANTS AND COMPOSITIONS | NOVO NORDISK A/S (DK) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999011770-A1 | PROTEASE VARIANTS AND COMPOSITIONS | NOVO NORDISK A/S (DK) | 1999-03-11 | — | — | WO | disclosed |